LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1) is a homolog of the hyaluronan receptor CD44, and one of the most widely used markers of lymphatic endothelial cells in normal and tumor tissues. However, the physiological role of LYVE-1 in the lymphatic system still remains unclear. It is well established that Fibroblast Growth Factor 2 (FGF2) induces lymphangiogenesis. Based on the known interaction between FGF2 and CD44 and based on the structural similarity of CD44 and LYVE-1, we investigated whether FGF2 might interact with LYVE-1. We found that FGF2 is able to bind LYVE-1 using AlphaScreen®, or after surfaceimmobilization or in solution. FGF2 binds to LYVE-1 with a higher affinity than any other known LYVE-1-binding molecules such as hyaluronan or PDGF-BB. Glycosylation of LYVE-1 is important for FGF2 binding. Furthermore, FGF2 interacts with LYVE-1 when overexpressed in CHO cells. Soluble LYVE-1 and knock-down of LYVE-1 in lymphatic endothelial cells impaired FGF2 signalling and functions. In addition, FGF2 but not VEGF-C-induced in vivo lymphangiogenesis, was also inhibited. Conversely, FGF2 also modulates LYVE-1 expression in cells and ex vivo. Thus, our data demonstrate a functional relationship to the interaction between FGF2 and LYVE-1.
Introduction
The lymphatic system is important to maintain fluid homeostasis by collecting fluid that leaks from capillary blood vessels and returning it to the blood circulation 1 . Perturbations in the development, maintenance and function of the lymphatic system can lead to a variety of pathological lymphatic disorders including lymphedema, inflammation and tumor metastasis 2 . The understanding of the molecular and cellular regulation of lymphangiogenesis has greatly advanced in recent years with the identification of the lymphangiogenic vascular endothelial growth factors VEGF-C and VEGF-D and their lymphatic vessel-specific VEGF receptor-3 3 . The repertoire of lymphangiogenic factors has been increased when it became apparent that other growth factor molecules or angiogenic factors were also regulating lymphangiogenesis [4] [5] [6] . As such it has been recognized that FGF2 induces lymphangiogenesis by both direct and indirect mechanisms; it binds lymphatic endothelial cells (LEC) and stimulates their proliferation and migration in vitro 7, 8 ; in addition recent findings suggested that FGF2 reciprocally interacts with VEGF-C leading to additive lymphangiogenic activity and metastasis 9, 10 .
LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1), a homolog of hyaluronan receptor CD44, is expressed predominantly on lymphatic endothelium 11 . It is equally exposed to both the luminal and subluminal face of lymphatic vessel 12 . LYVE-1 cDNA encodes a 322-residue type I integral membrane glycoprotein with a 21-residue transmembrane domain and a 63-residue cytoplasmic region. Like CD44, LYVE-1 has a single hyaluronan-binding domain at the Nterminus followed by a juxtamembrane region that is predicted to be heavily glycosylated 12 .
LYVE-1 is also expressed in discrete populations of activated tissue macrophages and in the sinusoidal endothelium of the liver and the spleen as well as in cancer tissues 11, [13] [14] [15] .
LYVE-1 has been proposed to participate in binding and internalization of hyaluronan (HA), a substrate for migrating lymphocytes that facilitates their transport to lymph nodes 16 . However, recent studies suggest that HA homeostasis is unperturbed in LYVE-1 -/-mice and that lymphatic adhesion/transmigration may be also mediated by other molecules than LYVE-1 17 .
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In parallel, CRSBP-1, a membrane glycoprotein that can mediate cell surface retention of platelet-derived growth factor-BB (PDGF-BB), was identified and characterized 18 . CRSBP-1 has been found to be identical to LYVE-1 19 . The biological properties of CRSBP-1 have been studied mainly using cultured fibroblasts. CRSBP-1 mediates the cell-surface retention of the simian sarcoma virus oncogene v-sis gene product (PDGF-BB) and insulin-like growth factor-binding protein-3 (IGFBP-3) in the simian sarcoma virus-transformed fibroblasts and in HI299 cells coexpressing CRSBP-1 and IGFBP-3 19 . However, the precise role of CRSBP-1/LYVE-1 remains unknown. It has been reported that CRSBP-1-null mice are overtly normal and fertile but exhibit identifiable morphological and functional alterations of lymphatic capillary vessels in only few tissues including the liver and the intestine 20 . Furthermore, PDGF-BB and HA enhance interstitiallymphatic flow in wild-type mice but not in CRSBP-1-null animals 20 . In conflict with these results, LYVE-1-deficient mice were reported to display a normal lymphatic vasculature and secondary lymphoid tissue with normal unperturbed HA homeostasis 17 .
Similarly, recent studies demonstrate the lack of a lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice under normal conditions 21 . As a consequence, the functional role of LYVE-1 protein is not firmly established and remains controversial.
As mentioned above, CD44 is the closest homolog of LYVE- 
Material and Methods

Cell lines
The following cell lines were used: Human Dermal Lymphatic Endothelial Cells (LEC, 
Cross-linking of FGF2 and LYVE-1
The amine-specific homobifunctional cross-linker bis(sulfosuccinimidyl) suberate (BS3; Pierce Biotechnology, USA) was used to cross-link FGF2 and LYVE-1 according to the protocol modified from Perollet et al 26 .
Tubulogenesis of LYVE-1 siRNA-treated LEC
Tubulogenesis of LYVE-1 siRNA LEC in the presence or absence of 50 ng/ml FGF2 was performed using IBIDI μ-slides (IBIDI, Germany) coated with 7µg/µL reduced matrigel. After 12-24h of incubation four digitized pictures were made per well and the images were processed with the Wimasis.com platform to determine the total branching points and the number of loops.
Cell proliferation, migration and invasion assays
LEC proliferation, migration and invasion assays were carried out using IncuCyte™ (Essen Bioscience).
Solid-phase ligand binding assay
Solid-phase ligand binding assay was performed as described previously with minor modifications 27 .
Statistics
Data are presented as mean ± SD. Statistical analyses were performed using unpaired Student's ttest. *, P<0.05; **, P<0.01; ***, P<0.001. 
Results
Identification and characterization of the interaction between FGF2 and LYVE-1
We used an amplified luminescence proximity homogeneous assay, AlphaScreen® to detect and measure the interaction between FGF2 and LYVE-1 28 . To configure an AlphaScreen® assay to monitor the interaction between FGF2 and LYVE-1, recombinant tagged proteins for FGF2 and LYVE-1 were used. FGF2 fused to GST was expressed in E. coli, purified using glutathioneSepharose affinity chromatography. The purity (supplemental Fig. 1A ) and the biological activity of FGF2 to stimulate endothelial cell proliferation were verified (supplemental Fig. 1B ). In addition, a commercial preparation of soluble extracellular part of LYVE-1 was used. In our assay, 27.2 ng/ml for heparin and 360 nM for PDGF-BB ( Fig. 1B and 1C ). We also carried-out a control assay for the interaction of LYVE-1 with FGF2 and used the unfolded response protein IRE1
instead of LYVE-1 in the AlphaScreen® (supplemental Fig. 2 ). In this assay, FGF2 was not able to interact with IRE1.
In addition to the AlphaScreen® proximity assay, we further analyzed the FGF2/LYVE-1 interaction by other assays. As shown in Fig We then performed co-immunoprecipitation experiments using both anti-FGF2 and anti-LYVE-1 antibodies (Fig. 2C) . These experiments revealed that FGF2/LYVE-1 complexes could be coimmunoprecipitated using either by anti-FGF2 or anti-LYVE-1 antibodies. Taken together, these data demonstrate that FGF2 directly interacts with LYVE-1 in vitro.
We next investigated whether glycosylation is important for the FGF2/LYVE-1 interaction.
Deglycosylation with PGNaseF led to a drastic decrease in the AlphaScreen® signal (supplemental Fig. 3 ). This indicates that glycosylation is important for the FGF2/LYVE-1 interaction.
Role of the FGF2/LYVE-1 interaction in LEC
We first examined whether the soluble extracellular part of LYVE-1 (sLYVE-1) inhibits FGF2-mediated effects in LECs. To this end, we conducted both migration and invasion assays using IncuCyte TM technology. As shown in Figure 3A and B, sLYVE-1 (250 ng/ml) inhibited FGF2 induced migration and invasion in a time-dependent manner. Moreover, VEGF-C induced migration was not inhibited by sLYVE-1 (supplemental Fig. 4A ). In addition, we also observed LYVE-1-dependent inhibition of FGF2-induced proliferation in the IncuCyte TM assay but not of apoptosis ( It is well known that FGF2 induces the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) by ERK kinase 29 . We observed a significant inhibition of ERK phosphorylation by LYVE-1 in LEC (Fg. 3D). Thus, these results indicate that sLYVE-1 acts on endothelial cell migration, invasion and on cell proliferation but not on apoptosis. This is in agreement with the inhibition of ERK phosphorylation. In a second approach, we investigated whether the down-regulation of membrane-bound LYVE-1 in LEC altered FGF2 activity. Knock-down of LYVE-1 in LEC was achieved using a pool of four LYVE-1 siRNAs or a selected LYVE-1 siRNA and resulted in the inhibition of LYVE-1 mRNA and protein (supplemental Fig. 5A ). We observed an inhibition of FGF2-stimulated LEC proliferation after knock-down of membrane LYVE-1 (Fig. 4A) . As a control, we attenuated LYVE-1 expression in VEGF-stimulated LECs. No significant inhibition of LEC proliferation was seen under this condition (supplemental Fig. 5B ). To ascertain the specificity of LYVE-1 siRNA for lymphatic cells, FGF2-stimulated blood vascular endothelial cells (BEC) were incubated with LYVE-1 siRNA. No effect of LYVE-1 siRNA was observed under these conditions (supplemental Fig. 5C ). This indicated the specificity of LYVE-1 siRNA for LECs that express LYVE-1. Finally, we observed an inhibition of FGF2-induced tubulogenesis when LYVE-1 was silenced ( Fig. 4B-D ). These data demonstrate that attenuation of LYVE-1 expression results in an inhibition of biological processes stimulated by FGF2.
Cell-based characterization of the FGF2-LYVE-1 interaction
We next examined whether the interaction of FGF2 and LYVE-1 occurs in cell culture. To this end, we cloned the full-length transmembrane LYVE-1 (tmLYVE-1) cDNA in the pcDNA3.1 vector, and stably transfected CHO cells that lack endogenous LYVE-1. After selection, several clones were obtained and analyzed for LYVE-1 mRNA expression using qPCR and for cell surface localization of LYVE-1 using immunofluorescence with an antibody specific for human LYVE-1 (supplemental Fig. 6A and B) . Quantitative cell attachment assay demonstrated that the LYVE-1 expressing cells were able to bind to immobilized HA 2 fold more than mock-transfected cells lacking LYVE-1 (Fig. 5A) . We then tested whether LYVE-1 expressed on the cell surface of Fig. 6C and D) . In contrast to FGF2 binding to low-affinity sites, LYVE-1 had no effect on 125 I-FGF2 binding to high-affinity sites (Fig. 5C ).
Effect of LYVE-1 on FGF2-induced lymphangiogenesis in vivo
To analyze the effect of LYVE-1 on lymphangiogenesis in vivo we applied a corneal lymphangiogenesis assay to quantitatively study the formation of new lymphatic vessels 32 . Earlier, it has been shown that FGF2 implanted in the mouse cornea stimulated lymphangiogenesis 7, 33 . To analyze the effect of LYVE-1 on FGF2-induced lymphangiogenesis, pellets containing FGF2 alone or a combination of FGF2/LYVE-1 were implanted in corneas of BALB/c mice ( Fig. 6A-E To ascertain the specificity, the effect of LYVE-1 on VEGF-C induced corneal lymphangiogenesis was investigated. VEGF-C-induced lymphangiogenesis and VEGF-C/LYVE-1-induced lymphangiogenesis did not differ significantly in the micropocket assay (supplemental Fig. 7A-E ).
This indicates that LYVE-1 does not inhibit the lymphangiogenic effect of VEGF-C in vivo.
For
FGF2-dependent regulation of LYVE-1 expression
To further characterize the interaction between FGF2 and LYVE-1 in lymphatic cells, we investigated whether FGF2 has an effect on LYVE-1 expression in LEC. Indeed, FGF2-stimulated LECs and HUVECs exhibited a maximum in LYVE-1 expression at 48h (Fig. 7A) . We next investigated whether FGF2 could reverse the TNFβ-dependent down-regulation of LYVE-1 34 .
LECs and HUVECs were stimulated with FGF2 for 24-72h in the presence of TNFβ . As expected, FGF2 was able to reverse the TNFβ-dependent down-regulation of LYVE-1 in both cell types (Fig. 7 B,C) . These results were confirmed by immunofluorescence labelling of LEC using anti-LYVE-1 antibodies. As seen in Figure 7D (right panel), FGF2 increases the fluorescent signal for LYVE-1, while TNFβ significantly diminishes it. In the presence of FGF2, immunoreactivity for LYVE-1 is restored. We then examined whether FGF-2 is able to counteract the effect of TNFβ on LYVE-1 expression in an ex vivo assay (Fig. 7E) . Ear explants from mice were exposed for 48 h to TNFβ (200 ng/ml) in the presence or absence of FGF2 (200 ng/ml). TNFβ clearly decreases the immunofluorescence signal for LYVE-1. This is no more observed when FGF2 is added together with TNFβ. Taken together, these results indicate that FGF2 positive regulates LYVE-1 expression in LEC and HUVEC and is able to counteract the inhibitory effect of TNFβ on LYVE-1 expression in vitro and ex vivo.
We then investigated whether the expression of endogenous LYVE-1 is downregulated in FGF2 knockout mice. Accumulating evidences indicate that LYVE-1 expression is not restricted to the lymphatic endothelium, but it is also expressed in the normal liver and spleen sinusoids, heart myocytes and lung macrophages 11, 13, 14, 35 . We isolated total RNA from liver, lung, spleen and heart of wild type male and female mice and examined the levels of LYVE-1 expression by qPCR (supplemental Fig. 8A ). We found abundant LYVE-1 expression in wild type tissue of lung, heart and liver, and low LYVE-1 levels in spleen. Furthermore, we observed that the levels of endogenous LYVE-1 were not identical in male and female mice, especially in liver and spleen.
Therefore we analyzed LYVE-1 expression levels in male and female FGF2 knockout mice
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From separately, normalizing them to LYVE-1 level in wild type tissues (n=5). We found that LYVE-1 expression levels were decreased only in the liver and spleen of male mice, while female showed no difference in LYVE-1 expression in these organs (supplemental Fig. 8B ). Thus FGF2 may positively regulate LYVE-1 expression in vivo in a tissue-specific manner. The data indicate that FGF2 is critical for LYVE-1 expression in liver and spleen sinusoids.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From DISCUSSION LYVE-1 is a lymphatic endothelial cell marker that is also expressed in some other cell types including activated tissue macrophages, the sinusoidal endothelium of liver and spleen, heart myocytes as well as some tumors 11, [13] [14] [15] 35 . However, its function is still not clearly elucidated. In this article, we report that a member of the FGF family, FGF2 can interact with LYVE-1 and that this interaction impacts on some of the FGF2-mediated effects in the lymphatic endothelium.
Furthermore, FGF2 can modulate LYVE-1's endogenous expression and reverse the effect of inflammatory cytokines.
We found that LYVE-1 binds FGF2 using AlphaScreen® technology. These results were reinforced using solid phase binding assays with surface immobilized FGF2 and injected LYVE-1.
Under these conditions, a significant binding was observed. The affinity as reflected by the calculated K D was of 100 nM and was 4-10 fold lower than those obtained for other LYVE-1 binding molecules tested including VEGFA, PDGF-BB, VEGFC, fibronectin and HA. This indicates a better affinity of LYVE-1 for FGF2 than for other binding molecules. We were also able to demonstrate that the FGF2/LYVE-1 complex occurred in solution using chemical crosslinking or co-immunoprecipitation experiments. Another observation of note is the fact that heparin and PDGF-BB were able to compete with the FGF2/LYVE-1 interaction. These findings indicate the existence of a probable overlapping binding site in LYVE-1 or FGF2 that also binds to heparin and PDGF-BB. Indeed, PDGF-BB has been reported to be an important growth factor contributing to lymphatic metastasis 36 and bind LYVE-1 18 and our observations are in line with these data. These data suggest that LYVE-1 may be involved in the modulation of VEGF-Cindependent lymphangiogenesis by directly interacting with critical lymphangiogenesis factors such as FGF2 or PDGF-BB. Moreover, it has also been reported that PDGF-BB directly interacts with FGF2 37 and thus PDGF-BB may also compete for LYVE-1 binding on FGF2. Heparin is known to be implicated in the dimerization of FGF2 and to modulate the interaction of FGF2 with We next sought to investigate whether LYVE-1 was able to alter some of FGF2's functions such as migration, invasion and proliferation. We observed that FGF2-stimulated migration, invasion and proliferation were inhibited in the presence of LYVE-1. We showed that FGF2-induced signalling was impaired by LYVE-1. These experiments were made by using both, LYVE-1 and siRNA for LYVE-1. Most importantly, sLYVE-1 is able to inhibit FGF2-induced lymphangiogenesis in vivo in a mouse corneal lymphangiogenesis assay. We were, however, unsuccessful in knocking-down LYVE-1 expression in the in vivo rat cornea assay using specific and validated siRNA for LYVE-1. Thus, the effect on FGF-2-induced lymphangiogenesis in vivo could not be investigated for membrane-bound LYVE-1.
Taken together, our results demonstrate that LYVE-1 is able to interfere with LEC function in vitro and in vivo. In agreement with our results it has been recently shown that LYVE-1 is involved in the disruption of VE-cadherin-mediated intercellular adhesion and opening of intercellular junctions in LEC monolayers4 43 . Furthermore, it has been demonstrated that the inhibition of FGF signalling is important for vascular integrity 44 . Indeed, blockade of FGF activity in vitro and in vivo results in dissociation of the VE-cadherin/p120-catenin complex and disassembly of adherent and tight junctions, which progress to loss of endothelial cells and disintegration of the vasculature. Thus, our results together with these observations point to an important interaction between FGFs and LYVE-1 in the lymphatic endothelium.
We also demonstrated that FGF2 not only interacts with LYVE-1 but can also induce its expression in LEC. More importantly, FGF2 is able to counteract the down-regulation of LYVE-1
by TNFβ in LEC. This is based on in vitro and ex vivo experimental evidences. It has been previously reported that LYVE-1 expression is down-regulated by TNFβ through internalization and degradation of receptors in lysosomes, coupled with a shutdown in gene expression 34 . This is quite remarkable and may be of importance in chronic inflammation where TNF is abundantly
TNF. In addition, it has been reported that FGF2 mediates a protective effect against TNFα-mediated apoptosis in HUVEC 45 . Recently, the presence of LYVE-1-negative gaps in the corneal lymphatic endothelium has been observed 46 . The number of gaps in FGF2, but not VEGFA implanted corneas was significantly lower than in untreated corneas, which indicates a potential stimulatory effect of FGF2 on LYVE-1 expression. Another hypothesis is that in some tumors, FGF2 overexpression may influence the lymphatic endothelial cell phenotype. It has been shown that PROX1, the homeobox-containing transcription factor expressed by LEC, is able to upregulate FGFR3 receptor in LEC 8 . Thus it is possible that FGF2 blocks external cues that negatively act on the lymphatic phenotype.
To reinforce the contention that FGF2 positively regulates LYVE-1 expression, we analysed whether FGF2 loss in FGF2 -/-mice led to a decrease of LYVE-1 expression in some of their organs. Indeed, we show a decrease in LYVE-1 expression in the liver and spleen of FGF2 -/-mice. These organs are responsible for the uptake and degradation of high molecular weight HA 11 .
Thus, FGF2 and LYVE-1 are possibly integrated in a regulatory loop, in which FGF2 activates LYVE-1 expression, which in turn, limits FGF2 activity by directly interacting with the growth factor.
In conclusion, we show for the first time that LYVE-1 is able to interact with one of the fibroblast growth factor members; namely FGF2. This interaction appears stronger than any of other known representative experiments done in duplicates (data points as mean ± SD, n=3). 
